Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Neoplasms × Acetaminophen × Clear all

Phase

Status

Sponsor Class

OTHER 7 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Multiple Myeloma 4 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Carcinoma, Non-Small-Cell Lung 2 Ulcer 1 Stomatitis 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Neurofibromatosis 1 1 Neoplasms 1 Neoplasm Metastasis 1 Melanoma 1 Lymphoma, Large B-Cell, Diffuse 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Head and Neck Neoplasms 1 Glioblastoma 1 Fallopian Tube Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Squamous Cell 1 Adenocarcinoma 1

Interventions

pembrolizumab 109 Paclitaxel 85 Gemcitabine 83 Carboplatin 72 Nivolumab 55 Docetaxel 54 Bevacizumab 53 Cisplatin 45 Pemetrexed 42 Fluorouracil 40 Cyclophosphamide 38 Cetuximab 31 Capecitabine 31 Leucovorin 30 venetoclax 29 Irinotecan 29 trametinib 28 atezolizumab 28 Sorafenib 28 Erlotinib Hydrochloride 26 Dexamethasone 25 130-nm albumin-bound paclitaxel 25 Drug Therapy 24 Ipilimumab 23 Epoetin Alfa 23 Doxorubicin 22 Oxaliplatin 20 Prednisone 19 Lapatinib 19 dabrafenib 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03554005 2019-07-15

MK-4031-009

Merck Sharp & Dohme LLC

Phase 1 Completed

29 enrolled 11 charts

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡